



April 26, 2017

## **Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC**

NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar, President & CEO, will present an overview at PIONEERS 2017 presented by Joseph Gunnar & Co., LLC.

### **Presentation Details:**

Date: Tuesday, May 2, 2017

Time: 8:30 am ET

Location: Mandarin Oriental Hotel, New York City

A recording of the presentation will be available on the [Investor Page](#) of Onconova's website and will be active for 90 days following the event.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with our lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit <http://www.onconova.com>.

### GENERAL CONTACT:

<http://www.onconova.com/contact/>

### INVESTOR RELATIONS CONTACT:

Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics

[Lisa.Sher@mbsvalue.com](mailto:Lisa.Sher@mbsvalue.com) / (212) 750-5800